Mirtazapine compared with paroxetine in major depression

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Major depressive disorder (MDD) is a prevalent mental health condition requiring effective treatment options.
• Comparing the efficacy and tolerability of different antidepressant medications is crucial for optimizing patient care.

Purpose of the Study:

• To compare the efficacy and tolerability of mirtazapine versus paroxetine in patients diagnosed with major depressive episode.
• To assess the onset of therapeutic action and symptom improvement over a six-week treatment period.

Main Methods:

• A randomized controlled trial involving 275 outpatients with MDD (DSM-IV criteria).
• Participants were assigned to receive either mirtazapine (15-45 mg/day) or paroxetine (20-40 mg/day) for six weeks.
• Efficacy was evaluated using the Hamilton Rating Scale for Depression (HAM-D-17) and Hamilton Rating Scale for Anxiety (HAM-A), with intent-to-treat analysis.

Main Results:

• Both mirtazapine and paroxetine were equally effective in reducing depressive symptoms after six weeks.
• Mirtazapine showed a significantly faster onset of action, with greater improvement in HAM-D-17 scores at week 1.
• Mirtazapine also demonstrated a more significant reduction in anxiety symptoms (HAM-A) at week 1 compared to paroxetine.

Conclusions:

• Mirtazapine and paroxetine are equally effective and well-tolerated treatments for major depressive disorder over a six-week period.
• Mirtazapine may offer a faster onset of therapeutic efficacy, particularly for core depressive symptoms and anxiety.
• Further research can explore long-term outcomes and specific patient subgroups benefiting from each medication.